You are here: Industry Insights > NTRK

News List

British Journal of Cancer: Zurletrectinib Is a Next-Generation TRK Inhibitor With Strong Intracranial Activity Against NTRK Fusion-Positive Tumors With On-Target Resistance to First-generation Agents July 31, 2024
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumors with on-target resistance to first-generation agents.
“Precise” “Broad-spectrum” – An Overview of NTRK Fusion-Targeted Oncology Drugs PharmaSources/Zongqin
June 17, 2020
According to the official website of the CDE recently, InnoCare Pharma’s ICP-723 tablets has received a clinical trial implied permission,
FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumors for Vitrakvi americanpharmaceuticalreview
November 02, 2020
The U.S. Food and Drug Administration (FDA) has approved the next-generation sequencing (NGS)-based FoundationOne CDx test (Foundation Medicine) as a companion diagnostic to identify fusions in neurotrophic receptor tyrosine kinase (NTRK) genes, NTRK1 ...
Rozlytrek Approved to Treat Tumors With NTRK Gene Fusion drugs
August 20, 2019
Rozlytrek (entrectinib), a kinase inhibitor, has received approval to treat adults and adolescents with cancer that carries the genetic defect neurotrophic tyrosine receptor kinase (NTRK) gene fusion and...
FDA grants Rozlytrek cancer treatment approval drugs
August 19, 2019
The cancer therapeutic, Rozlytrek, has gained FDA approval as well as Priority Review, Breakthrough Therapy and Orphan Drug Designations.
FDA Approves Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors drugs
August 16, 2019
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive...
Japan becomes the first country to approve Roche's personalised medicine Rozlytrek worldpharmanews
June 20, 2019
Japan becomes the first country to approve Roche's personalised medicine Rozlytrek.
Japan First to Approve Roche’s Rozlytrek contractpharma
June 19, 2019
A tumor-agnostic medicine for treatment of adult and pediatric patients with NTRK fusion-positive advanced recurrent solid tumors/
Roche's personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents worldpharmanews
May 21, 2019
Roche's personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents.
Bayer/Loxo drug approved in cancers with certain mutation pharmaphorum
November 30, 2018
The FDA has approved Bayer and Loxo’s Vitravki (larotrectinib) for adults and children whose cancers have a specific genetic feature, or biomarker.

Previous page 1 2 Next page